{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:39:15Z","timestamp":1784885955425,"version":"3.55.0"},"reference-count":25,"publisher":"Informa UK Limited","issue":"23","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020540","name":"Coherus BioSciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020540","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.2217\/fon-2022-0365","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T13:00:51Z","timestamp":1655384451000},"page":"2551-2560","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1212-9894","authenticated-orcid":false,"given":"Kyle","family":"Kitchen","sequence":"first","affiliation":[{"name":"Clinical Services Department,Utah Cancer Specialists,\rSalt Lake City,\rUT 84124,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C","family":"Mosier","sequence":"additional","affiliation":[{"name":"Biostatistics Department,EMB Statistical Solutions,LLC,\rOverland Park,\rKS 66210,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"National Comprehensive Cancer Network\n. NCCN Clinical Practice Guidelines in Oncology. Hematopoietic growth factors Version 1.2022. (2022)."},{"key":"e_1_3_5_4_1","unstructured":"National Cancer Institute\n. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. (2006). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.10.013"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.019588"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2686-9"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw325"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-6-427"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006288731"},{"key":"e_1_3_5_11_1","unstructured":"NEULASTA \u00ae (pegfilgrastim) injection for subcutaneous use. Amgen Inc CA USA (2020). www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/neulasta\/neulasta_pi_hcp_english.pdf"},{"key":"e_1_3_5_12_1","unstructured":"FULPHILA\u2122 (pegfilgrastim-jmdb) injection for subcutaneous use. Mylan Institutional LLC IL USA (2021). if you still need the link: IL USA (2019). https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=3ea915d7-2feb-4e75-91f7-913c965b7d8a&type=display"},{"key":"e_1_3_5_13_1","unstructured":"UDENYCATM (pegfilgrastim-cbqv) injection for subcutaneous use. Coherus Biosciences CA USA (2018). https:\/\/udenyca.com\/pdf\/udenyca-pi.pdf"},{"key":"e_1_3_5_14_1","unstructured":"ZIEXTENZO\u2122 (pegfilgrastim-bmez) injection for subcutaneous use. Sandoz Inc NJ USA (2019). https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=7dada041-6528-4acf-809c-62d271538c9a"},{"key":"e_1_3_5_15_1","unstructured":"NYVEPRIA\u2122 (pegfilgrastim-apgf) injection for subcutaneous use. Hospira Inc IL USA (2020). https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=13622"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00994"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106591"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.12968\/pnur.2014.25.9.451"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.12968\/jorn.2012.4.2.81"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220956305"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4513-6"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.091094"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000115"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.4357.4357"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.e18562"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e18687"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0532"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:14Z","timestamp":1719125174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":25,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.2217\/fon-2022-0365"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0365","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}